Kendle was the only contract research organisation (CRO) to make this year’s list of the 100 fastest-growing companies in the US published by Fortune magazine.

The US-based CRO ranked 67th on the Fortune 100 list, based on three years of revenue and profit growth as well as total returns in data provided by Zacks Investment Research. As Kendle noted, its three-year annual compounded results delivered earnings and revenue growth of 27% and 44% respectively, while total returns came in at 34%.

The CRO is on track for continued strong growth in the current fiscal year, with earnings per share (EPS) projected to increase by 59-71% over reported EPS of US$1.126 for fiscal 2007, it added. Last month Kendle raised its guidance for full-year service revenues and earnings per share after registering growth of 30% and 49% respectively in net revenues and operating profit for the second quarter.

According to chairman and chief executive officer Candace Kendle, the company remains “focused on our customer and business expansion strategy to position Kendle as a best-in-class drug development partner … We look forward to driving continued future growth in our business and to leveraging the increasing strength of our global organisation to capitalise on strong demand for Phase I through IV outsourcing services”.

The company’s share price has been responding in kind. Local newspaper The Cincinnati Enquirer noted that, in a volatile market, Kendle ended the third quarter of 2008 at US $44.71, up by 23.1% during the quarter and 7.7% for the year.